Ajaya
Delaware corporation · 1 known investors
Ajaya develops precision antibodies designed to selectively remove disease-causing immune cells while preserving healthy immune function, targeting autoimmune disease treatment.
Biotechin /ajaya-bio
Founders & leadership
MS
Mohit SachdevaExecutive Officer, Director
Investors · 1
Reported raises · per SEC filings
Form D private placements▶$150KraisedJul 2024 · 2 investors · Other TechnologyRule 506(b)
▶$150KraisedJul 2024 · 2 investors · Other Technology
Rule 506(b)Officers, directors & promoters on the filing
- Mohit SachdevaExecutive Officer, Director
- Offering amount
- $300K
- Amount sold
- $150K
- First sale
- Apr 2024
- Incorporated
- Corporation, Delaware, 2024
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
In the news
- Commercial papers explained: How companies raise short-term funds | Company News - Business Standardbusiness-standard.com · 2026
- Ajaya Bio plans Series A to advance autoimmune treatment and grow in Philadelphiatechnical.ly · 2026
- Payments firm Juspay raises $60 mn days after open-sourcing routing layer | Company News - Business Standardbusiness-standard.com · 2025
- CURRYiT has raised INR 4.5 Cr in Seed funding round co-led by RK Family Trust, Tangent Advisors, and Freeflow Ventures. - Enablersenablersinvestment.com · 2024
- CURRYiT raises Rs 4.5cr in seed round to scale-up manufacturing & distributionbusiness-standard.com · 2024